Dr. Beckermann on Investigational Treatment Strategies in mRCC


Kathryn E. Beckermann, MD, PhD, discusses investigational treatment strategies in metastatic renal cell carcinoma.

Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses investigational treatment strategies in metastatic renal cell carcinoma (mRCC).

VEGF inhibitors and mTOR inhibitors are used to target VHL loss, says Beckermann. Given the success of these agents, investigators are searching for other targets in the pathway.

Additionally, combinations of PD-1 and CTLA-4 inhibitors, and PD-1/PD-L1 and VEGF inhibitors have shown improved response rates in patients with mRCC, explains Beckermann.

Triplet regimens are being explored to determine whether overall responses and disease control can be improved without sacrificing the tolerability and safety of treatment, concludes Beckermann.

Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD